Cargando…
Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
Spironolactone was first developed over 50 years ago as a potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more MR-specific. From a marginal role as a potassium-sparing diuretic, spironolactone...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796852/ https://www.ncbi.nlm.nih.gov/pubmed/24133375 http://dx.doi.org/10.2147/IBPC.S13783 |